查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837196

獸用/獸用疫苗市場（依動物種類、疫苗技術、給藥途徑、疾病類型及最終用戶分類）－2025-2032年全球預測

Veterinary/Animal Vaccines Market by Animal Type, Vaccine Technology, Route Of Administration, Disease Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，獸用/動物疫苗市場規模將達到 166.5 億美元，複合年成長率為 7.15%。

關鍵市場統計數據
基準年2024年 95.8億美元
預計年份：2025年 102.8億美元
預測年份 2032 166.5億美元
複合年成長率 (%) 7.15%

全面概述獸用疫苗市場格局，重點介紹關鍵促進因素、相關人員的作用、技術進步以及影響策略的監管環境。

獸用疫苗領域正經歷一場結構性變革，這場變革正在改變科學範式、商業策略以及生產者和服務供應商的企業發展方式。來自研究機構、臨床機構、農業營運機構和監管機構的相關人員正圍繞著一個通用目標匯聚：改善疾病控制、提升動物福利並建立更具韌性的供應鏈。隨著科學基礎擴展到先進的免疫學平台和數位健康工具，疫苗研發者和經銷商的角色也從單純的產品供應商轉變為提供端到端預防和監測解決方案的綜合合作夥伴。

此外，儘管監管制度在原則上日益趨於統一，但在實踐中仍然存在差異，迫使企業制定兼顧本地合規性和全球擴充性的監管策略。同時，消費者和生產商對安全性、可追溯性和永續性的期望不斷提高，這也提高了產品證據和生命週期透明度的要求。各組織必須優先考慮平台投資，促進跨產業夥伴關係，並調整商業模式以適應不斷變化的終端用戶行為。本導言從實證角度分析了技術進步、貿易動態和市場片段化如何相互作用，從而為獸用疫苗領域帶來眼前的挑戰和長遠的機會。

突破性的科學突破、平台創新以及相關人員優先事項的轉變，正在重新定義動物疫苗的研發、供應和應用。

過去十年間，動物健康領域發生了多項變革性轉變，重塑了疫苗的發現、生產、交付和應用方式。其中一項關鍵的科學變革是平台技術的成熟，這些技術加速了抗原發現並實現了疫苗的模組化配置。這些平台縮短了研發週期，並有助於對新出現的病原體做出快速反應。同時，精準畜牧業和數位監測系統正在產生更高解析度的流行病學數據，從而形成反饋迴路，以前所未有的速度指導疫苗的設計和部署策略。

在商業性，人們越來越重視以價值為導向的提案，強調疾病預防、牛健康最佳化​​和綜合服務交付的經濟效益。策略性近岸外包、產能冗餘和多元化的供應商網路正成為標準的風險緩解策略。監管方面的演變也顯而易見，一些司法管轄區在保持嚴格的安全性和有效性標準的同時，為新型平台引入了簡化的試驗途徑。這些轉變的匯聚意味著，能夠整合科學敏捷性、數據主導決策和穩健商業模式的組織將獲得巨大的優勢。因此，領導者必須協調研發重點、生產投資和相關人員參與，才能掌握這項結構性轉變所帶來的正面影響。

分析美國關稅政策對2025年動物疫苗供應鏈、生產選擇、定價及全球貿易格局的累積影響

2025年美國關稅政策調整引入了複雜的貿易機制，對獸用疫苗產業的全球供應鏈和籌資策略產生了影響。累積效應導致疫苗生產所需的生物原料、特殊試劑和設備的進口投入成本上升，促使生產商重新評估籌資策略和成本轉嫁方式。為此，許多公司爭相尋找替代供應商，並考慮將生產基地遷至或擴大規模，以靠近需求中心，以減輕關稅的影響。

這種轉變也影響了與經銷商和大型買家（例如經銷商生產商和連鎖獸醫診所）的商業價格談判和合約結構。採購團隊要求提高到岸成本和庫存計畫的透明度，這反過來又迫使製造商加強其供應鏈分析和情境規劃能力。隨著企業將採購轉向關稅更優惠的合作夥伴，貿易轉移模式開始出現，但這種重組也帶來了次要風險，包括更長的資質認證週期、供應商品質波動以及需要提交額外的監管文件。

從策略角度來看，關稅環境加速了兩個長期趨勢：一是更重視策略性SKU的在地化生產經濟效益；二是為關鍵投入品建構供應商冗餘體系。先前已投資於靈活生產平台的企業發現，調整生產結構和維持供應連續性變得更加容易。展望未來，企業必須持續改善籌資策略，積極與貿易和監管相關人員溝通，並制定既能保障客戶獲得必要疫苗，又能應對未來潛在政策衝擊的商業協議。

透過對動物種類、疫苗技術、給藥途徑、疾病類別和最終用戶進行深度細分，挖掘針對性機會和風險。

按物種、平台、給藥途徑、疾病和最終用途進行細分，為將宏觀趨勢轉化為目標策略提供了切實可行的視角。就動物類型而言，市場涵蓋水產養殖、牛、伴侶動物、馬、家禽和豬，其中伴侶動物又細分為貓狗。疫苗技術選擇多樣，包括結合疫苗、去活化疫苗、減毒活疫苗、重組疫苗、次單元疫苗和類毒素疫苗。給藥途徑——注射、鼻內和口服——影響疫苗的普及曲線和給藥成本，而非侵入性給藥途徑則為大規模生產系統減輕勞動力負擔提供了機會。

疾病類型細分（針對細菌、寄生蟲和病毒）有助於研發優先排序和監測投資，因為病原體生物學和流行病學決定了徹底免疫和疾病緩解的可行性。最後，終端使用者細分（診所、農場和獸醫院，其中農場進一步細分為水產養殖、畜牧養殖、馬匹養殖場、家禽養殖場和生豬養殖場）有助於明確分銷管道和售後服務需求。例如，水產養殖和家禽養殖著重於大規模給藥物流和給藥技術，而診所和獸醫院則優先考慮伴侶動物品牌、安全性以及客戶溝通工具。整合這些細分觀點，企業可以設計出使產品屬性與使用者支付意願、營運限制和監管要求相符的產品組合策略，從而提高產品接受度和生命週期管理效率。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和比較優勢揭示了需求模式、製造地和法規環境。

區域動態影響企業在製造地、監管規劃和市場策略方面的策略選擇。在美洲，需求主要集中在伴侶動物照護和商業畜牧生物安全領域，這得益於成熟的經銷網路和獸醫服務系統。西歐對高階伴侶動物產品和先進的動物福利標準有著很高的需求，而其他地區則面臨著監管能力和疾病流行程度的差異，因此需要採取適應性的註冊和證據策略。在亞太地區，水產養殖業的快速成長以及家禽和豬肉生產的不斷加強帶來了巨大的機遇，但企業必須應對不同的管理體制、當地的生產獎勵，以及某些市場對本地化生產解決方案日益成長的偏好。

這些區域差異顯示了不同的投資重點。以美洲為中心的策略強調品牌建立、以數據主導的診所和獸醫院價值提案以及整合的客戶參與。歐洲、中東和非洲需要靈活的監管團隊和量身定做的市場推廣計劃，而亞太地區則需要擴充性的生產方案、與當地公司夥伴關係以及對疾病監測進行投資，以反映該地區的疾病負擔。將全球研發平台與特定區域的商業化策略結合的公司，更有可能在這三大區域實現更快的市場推廣和更高的營運效率。

競爭格局以及主要企業和創新者的策略性舉措正在影響動物疫苗的夥伴關係、併購活動、產能投資和平台差異化。

獸用疫苗市場的競爭格局由規模和創新兩大支柱所構成。歷史悠久的獸用疫苗老字型大小企業在分銷網路、監管專業知識和大規模生產能力方面保持優勢，使其能夠服務於包括大型農場和全球連鎖獸醫院在內的廣泛終端用戶群體。然而，規模較小的生技公司和平台創新者正日益崛起，它們率先開發重組構建體、載體疫苗和新型佐劑系統，從而提高疫苗的有效性、安全性和給藥便利性。受託製造廠商（CDMO）發揮著重要作用，它們使現有企業和新參與企業都能在無需投入大量資金建設端到端生產設施的情況下擴大生產規模。

策略性舉措包括有針對性的併購以彌補能力缺口，合作開發夥伴關係以加速平台檢驗，以及授權協議以實現在地化生產並保護核心智慧財產權。優先考慮平台靈活性和模組化生產的公司能夠快速調整抗原和物種，從而提升其應對需求波動的競爭優勢。此外，投資於現場支援（例如低溫運輸解決方案、農場管理人員培訓計劃和數位監測工具）的公司可以透過減少實施摩擦來脫穎而出。總而言之，競爭格局正在從單一產品提案轉向將科學差異化、卓越營運和以客戶為中心的服務相結合的整合解決方案。

為產業領導者提供切實可行的策略建議，以充分利用技術、供應鏈韌性、監管參與和以客戶為中心的商業化方法。

領導者應在技術、供應鏈、監管和商業等各個層面採取果斷行動，將市場複雜性轉化為競爭優勢。優先投資於能夠實現抗原敏捷且可擴展生產的平台技術，重點關注重組和模組化方法，以加快概念驗證速度并快速應對不斷變化的病原體情況。同時，應實現關鍵投入品供應商網路的多元化，並制定緊急時應對計畫，包括合格的替代供應來源和靈活的生產方式，以應對地緣政治和關稅方面的衝擊。

我們將加強與監管機構的溝通，並調配資源以協調各重點區域的申報工作，並參與政策對話，為新型平台製定加速核准路徑。在商業性，我們將調整市場區隔模型，使其與實際市場狀況相符。我們將與診所和獸醫院建立合作關係，促進伴侶動物的領養，並為水產養殖、家禽養殖、畜牧養殖、馬匹養殖和生豬養殖等農場設計大規模給藥和給藥解決方案。我們將利用數位化工具進行監控、上市後證據產生和客戶支持，以建立信任並展現成功。最後，我們將尋求與契約製造、學術合作夥伴和當地市場領導者建立策略聯盟，以在保持產品選擇和快速上市的同時，平衡規模和創新。

一種嚴謹的調查方法，包括一手訪談、二手資訊、法規和專利分析、臨床證據評估以及多源資料三角驗證方法。

本分析所依據的研究整合了定性和定量數據，以確保其穩健性和實用性。主要研究包括對疫苗研發企業高管、生產企業領導者、監管專家以及大型終端用戶（例如綜合農業企業和多站點獸醫診所）進行結構化訪談。次要分析則依賴於同行評審文獻、監管指導文件、臨床試驗註冊資訊、專利申請以及公司公開披露的資訊，以驗證趨勢並檢驗有關技術成熟度和商業行為的論點。供應鏈映射和情境分析評估了貿易政策變化的影響，並分析了關稅主導的採購轉變的影響。

為確保資料完整性，我們交叉檢驗了多個獨立資訊來源，並在專家研討會上檢驗了各種假設。對於存在的資訊缺口，我們開展了有針對性的後續訪談，並與供應商進行了討論，以澄清製造時間表、平台功能和區域法規等方面的細微差別。該調查方法兼顧了深度和透明度，使相關人員能夠理解結論的依據及其對策略規劃、風險管理和投資優先順序的實際意義。

風險概述、策略機會及優先行動方案，旨在應對技術變革、貿易逆風和不斷變化的終端用戶期望。

總之，獸用疫苗產業正處於一個戰略曲折點，科學創新、政策動態和不斷變化的終端用戶期望正在交匯融合，重塑競爭優勢。抗原設計和平台靈活性的技術進步為伴侶動物、家畜和水產養殖的疾病控制開闢了新的途徑，而貿易和關稅壓力則凸顯了供應鏈韌性和適應性籌資策略的必要性。按動物類型、疫苗技術、給藥途徑、疾病目標和終端用戶背景進行細分，可以為優先投資和定製商業化計劃提供切實可行的框架。

那些能夠開發平臺與營運彈性結合、投資於跨區域監管能力、並建立將科學差異化與生產規模結合的夥伴關係關係的管理者，將最有利於獲取長期價值。那些擁有系統思維、能夠整合監測、疫苗接種計劃和上市後證據生成，從而為動物健康、生產者經濟效益和公共衛生目標帶來實際成果的組織，將佔據有利地位。憑藉嚴謹的執行力和策略遠見，相關人員可以將當前的挑戰轉化為永續的競爭優勢。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大mRNA疫苗平台規模，以快速應對新出現的動物疾病
  • 整合數位追蹤技術，即時監測牲畜疫苗低溫運輸完整性
  • 開發單劑量即可針對多種通用感染疾病的多效價疫苗
  • 奈米顆粒佐劑系統在增強獸用疫苗免疫抗原性的應用日益廣泛
  • 為控制家禽地方病原體，自建疫苗生產設施的投資激增
  • 為簡化全球各獸醫監管機構之間的疫苗核准，各方正努力協調監管措施。
  • 重組病毒載體平台的進步提高了伴侶動物疫苗的安全性和有效性。
  • 植物疫苗表現系統因其成本低廉且可規模化，正日益受到關注，尤其是在動物免疫方面。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依動物類型分類的獸藥/獸用疫苗市場

  • 水產養殖
  • 牛
  • 伴侶動物
    • 貓
    • 狗
  • 馬
  • 家禽
  • 豬

9. 依疫苗技術分類的獸用/獸用疫苗市場

  • 結合疫苗
  • 不活化疫苗
  • 活病毒疫苗
  • 重組
  • 次單元
  • 類毒素

第10章 依給藥途徑分類的獸用/獸用疫苗市場

  • 注射
  • 鼻腔
  • 口服

第11章 獸藥/獸用疫苗市場（依疾病類型分類）

  • 細菌
  • 寄生蟲
  • 病毒性的

第12章：獸藥/獸用疫苗市場（依最終用戶分類）

  • 診所
  • 農場
    • 水產養殖場
    • 牛
    • 馬術設施
    • 家禽養殖場
    • 養豬場
  • 獸醫診所

第13章：依地區分類的獸藥/獸用疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 獸藥/獸用疫苗市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國獸藥/獸用疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Boehringer Ingelheim GmbH
    • Merck Animal Health
    • Zoetis Inc.
    • Hester Biosciences Limited
    • Indian Immunologicals Ltd.
    • Elanco Animal Health Incorporated
    • Ceva Sante Animale
    • Phibro Animal Health Corporation
    • Huvepharma
    • Arko Laboratories
    • Anicon Labor GmbH
    • Kemin Industries
    • Hipra
    • Vaxxinova
    • Pfizer, Inc.
    • Dechra Pharmaceuticals Limited
    • Bimeda Biologicals Inc
    • Neogen Corporation
Product Code: MRR-034B500303A8

The Veterinary/Animal Vaccines Market is projected to grow by USD 16.65 billion at a CAGR of 7.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.58 billion
Estimated Year [2025] USD 10.28 billion
Forecast Year [2032] USD 16.65 billion
CAGR (%) 7.15%

Comprehensive overview of the veterinary vaccines landscape revealing key drivers, stakeholder roles, technological progress, and regulatory interactions shaping strategies

The veterinary vaccines domain is in the midst of a structural transformation that is altering scientific paradigms, commercial strategies, and the operational footprints of manufacturers and service providers. Stakeholders across research institutions, clinical practice, farming operations, and regulatory bodies are converging around shared objectives: improved disease control, enhanced animal welfare, and resilient supply chains. As the scientific base expands to include advanced immunology platforms and digital health tools, the roles of vaccine developers and distributors are evolving from pure product suppliers to integrated partners offering end-to-end prevention and surveillance solutions.

Moreover, regulatory systems are increasingly harmonized in principle but remain heterogeneous in practice, prompting firms to design regulatory strategies that balance regional compliance with global scalability. Concurrently, consumer and producer expectations for safety, traceability, and sustainability are raising the bar for product evidence and lifecycle transparency. Taken together, these dynamics demand strategic clarity: organizations must prioritize platform investments, cultivate cross-sector partnerships, and align commercial models with shifting end-user behaviors. This introduction sets the stage for an evidence-driven exploration of how technological advances, trade dynamics, and market segmentation intersect to create both immediate challenges and durable opportunities in the veterinary vaccines landscape.

How transformative scientific breakthroughs, platform innovations, and shifting stakeholder priorities are redefining vaccine development, delivery, and adoption across species

The last decade has seen several transformative shifts that are recalibrating how vaccines are discovered, produced, delivered, and adopted across animal health sectors. A significant scientific shift is the maturation of platform technologies that accelerate antigen discovery and enable modular vaccine constructs; these platforms shorten development cycles and facilitate rapid responses to emergent pathogens. In parallel, precision livestock farming and digital surveillance systems are generating higher-resolution epidemiological data, creating feedback loops that inform vaccine design and deployment strategies more rapidly than before.

Commercially, there is a pronounced pivot toward value-based propositions that emphasize disease prevention economics, herd health optimization, and integrated service offerings-moving beyond transactional sales of products to subscription-style or outcome-oriented contracts. Supply chains are being redesigned for resilience: strategic nearshoring, capacity redundancy, and diversified supplier networks are becoming standard risk mitigants. Regulatory evolution is also notable, with some jurisdictions experimenting with streamlined pathways for novel platforms while maintaining rigorous safety and efficacy standards. These converging shifts mean that organizations able to integrate scientific agility, data-driven decision-making, and robust commercial models will gain disproportionate advantage. Consequently, leaders must align R&D priorities, manufacturing investments, and stakeholder engagement to capture the upside of these structural transitions.

Analyzing the cumulative effects of United States tariff policies in 2025 on supply chains, manufacturing choices, pricing dynamics, and global trade patterns for animal vaccines

United States tariff policy adjustments in 2025 introduced a layer of trade complexity that reverberated across global supply chains and procurement strategies in the animal health sector. The cumulative effect increased imported input costs for raw biological materials, specialized reagents, and equipment used in vaccine manufacturing, prompting manufacturers to reassess sourcing strategies and cost pass-through approaches. In response, many firms expedited qualification of alternative suppliers and evaluated relocation or expansion of manufacturing capacity closer to demand centers to mitigate tariff exposure.

These shifts also influenced commercial pricing negotiations and contract structures with distributors and large purchasers such as integrated producers and veterinary chains. Procurement teams sought greater transparency around landed costs and inventory planning, which in turn pushed manufacturers to strengthen supply chain analytics and scenario planning capabilities. Trade diversion patterns emerged as companies shifted procurement to tariff-favored partners, yet such reconfiguration created secondary risks including longer qualification timelines, variable supplier quality, and the need for additional regulatory filings.

From a strategic perspective, the tariff environment accelerated two durable trends: the economics of localized manufacturing for strategic SKUs and the emphasis on building supplier redundancy for critical inputs. Firms that had previously invested in flexible manufacturing platforms found it easier to adapt production mixes and maintain supply continuity. Looking ahead, organizations must continue to refine sourcing strategies, engage proactively with trade and regulatory stakeholders, and structure commercial agreements that recognize the potential for future policy shocks while preserving customer access to essential vaccines.

Deep segmentation insights across animal types, vaccine technologies, administration routes, disease categories, and end users to uncover targeted opportunities and risks

Segmentation offers a practical lens to translate macro trends into targeted strategies by species, platform, administration route, disease, and end-use context. When considering animal type, the market spans aquaculture, cattle, companion animals, equine, poultry, and swine with companion animals further dissected into cats and dogs-each subcategory exhibits distinct purchase drivers, dosing paradigms, and regulatory pathways that demand tailored commercialization approaches. On vaccine technology, choices range from conjugate, killed/inactivated, live attenuated, recombinant, subunit, to toxoid platforms; each technology carries trade-offs in manufacturing complexity, cold-chain demands, and differentiating claims, and therefore requires distinct pricing and evidentiary strategies. Route of administration-injectable, nasal, and oral-shapes adoption curves and administration cost profiles, with noninvasive routes presenting opportunities to lower labor burdens in mass production systems.

Disease type segmentation across bacterial, parasitic, and viral targets informs R&D prioritization and surveillance investments since pathogen biology and epidemiology dictate the feasibility of sterilizing immunity versus disease mitigation. Finally, end-user segmentation across clinics, farms, and veterinary hospitals-with farms further delineated into aquaculture farms, cattle farms, equine facilities, poultry farms, and swine farms-clarifies distribution channels and after-sales service needs; for example, aquaculture and poultry operations emphasize bulk dosing logistics and administration technologies, while clinics and veterinary hospitals prioritize companion animal brands, safety profiles, and client communication tools. Integrating these segmentation perspectives enables firms to design portfolio strategies that match product attributes with user willingness to pay, operational constraints, and regulatory requirements, thereby improving product uptake and lifecycle management.

Regional dynamics and comparative advantages across the Americas, Europe Middle East and Africa, and Asia-Pacific revealing demand patterns, manufacturing hubs, and regulatory climates

Regional dynamics materially shape strategic choices in manufacturing footprint, regulatory planning, and go-to-market approaches. In the Americas, demand is disproportionately weighted toward companion animal care and commercial livestock biosecurity, supported by established distribution networks and a mature veterinary services sector; the regulatory environment is characterized by well-developed pathways but significant expectations for clinical and safety data. In Europe, Middle East & Africa, heterogeneity is the primary challenge: Western Europe displays high demand for premium companion animal products and progressive animal welfare standards, while other subregions feature variable regulatory capacity and differing disease prevalence that call for adaptable registration and evidence strategies. In the Asia-Pacific region, rapid growth of aquaculture and intensification of poultry and swine production present large-scale opportunities, but companies must navigate diverse regulatory regimes, local manufacturing incentives, and a rising preference for locally produced solutions in some markets.

These regional contrasts suggest distinct investment priorities: Americas-focused strategies emphasize branding, data-driven value propositions for clinics and veterinary hospitals, and integrated customer engagement; Europe, Middle East & Africa requires flexible regulatory teams and tailored market-access plans; Asia-Pacific calls for scalable production options, partnerships with local players, and disease surveillance investments that reflect regional burden. Firms that harmonize global R&D platforms with region-specific commercialization playbooks will achieve faster adoption and higher operational efficiency across these three broad territories.

Competitive landscape and strategic moves by leading companies and innovators shaping partnerships, M&A activity, capacity investments, and platform differentiation in animal vaccines

Competitive dynamics in veterinary vaccines are characterized by a dual axis of scale and innovation. Established animal health companies retain advantages in distribution reach, regulatory expertise, and large-scale manufacturing capacity, enabling them to serve broad end-user bases such as major farming operations and global veterinary chains. However, smaller biotechnology firms and platform innovators are increasingly influential, pioneering recombinant constructs, vectored vaccines, and novel adjuvant systems that can improve efficacy, safety, and administration convenience. Contract development and manufacturing organizations (CDMOs) play an outsized role by enabling both incumbents and new entrants to scale production without the capital intensity of owning end-to-end facilities.

Strategic behaviors include targeted M&A to fill capability gaps, co-development partnerships to accelerate platform validation, and licensing arrangements that regionalize manufacturing while protecting core IP. Companies that emphasize platform flexibility and modular manufacturing gain the ability to pivot across antigens and species rapidly, creating competitive insulation against demand swings. Additionally, firms investing in field-level support-such as cold-chain solutions, training programs for on-farm administration, and digital monitoring tools-differentiate themselves by reducing adoption friction. In sum, the competitive battleground is shifting from single-product propositions to integrated solutions that combine scientific differentiation with operational excellence and customer-centric services.

Actionable strategic recommendations for industry leaders to capitalize on technology, supply chain resilience, regulatory engagement, and customer-centric commercialization approaches

Leaders should act decisively across technology, supply chain, regulatory, and commercial dimensions to convert market complexity into competitive advantage. Prioritize investment in platform technologies that enable antigen agility and scalable production, focusing on recombinant and modular approaches that reduce time to proof-of-concept and allow rapid response to shifting pathogen landscapes. Simultaneously, diversify supplier networks for critical inputs and develop contingency plans that include qualified alternate sources and flexible manufacturing arrangements to withstand geopolitical and tariff-related disruptions.

Strengthen regulatory engagement by allocating resources to harmonize dossiers across major territories and by participating in policy dialogues that shape accelerated pathways for novel platforms. Commercially, tailor go-to-market models to segmentation realities: cultivate relationships with clinics and veterinary hospitals for companion animal adoption, and design bulk dosing and administration solutions for farms, including aquaculture farms, poultry farms, cattle farms, equine facilities, and swine farms. Leverage digital tools for surveillance, post-market evidence generation, and customer support to build trust and demonstrate outcomes. Finally, pursue strategic collaborations with contract manufacturers, academic partners, and local market leaders to combine scale with innovation while preserving optionality and speed to market.

Rigorous research methodology describing primary interviews, secondary sources, regulatory and patent analysis, clinical evidence appraisal, and multi-source data triangulation approach

The research underpinning this analysis synthesized qualitative and quantitative inputs to ensure robustness and practical relevance. Primary research included structured interviews with senior executives across vaccine developers, manufacturing leaders, regulatory experts, and large end users such as integrated farming operations and multi-site veterinary practices. Secondary analysis drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, patent filings, and public corporate disclosures to triangulate trends and validate claims about technological readiness and commercial behavior. Supply chain mapping and scenario analysis were used to assess exposure to trade policy shifts and to evaluate the implications of tariff-driven sourcing pivots.

Data integrity was maintained through cross-validation across multiple independent sources and by testing alternative hypotheses during expert workshops. Where gaps existed, targeted follow-up interviews and vendor discussions were commissioned to ensure clarity on manufacturing timelines, platform capabilities, and regional regulatory nuances. The methodological approach balances depth and transparency, enabling stakeholders to understand both the evidence basis for conclusions and the practical implications for strategic planning, risk management, and investment prioritization.

Concluding synthesis of risks, strategic opportunities, and priority actions to navigate technological change, trade headwinds, and evolving end-user expectations in veterinary vaccines

In conclusion, the veterinary vaccines sector stands at a strategic inflection point where scientific innovation, policy dynamics, and evolving end-user expectations converge to reshape competitive advantage. Technological advances in antigen design and platform flexibility open new avenues for disease control across companion animals, livestock, and aquaculture, while trade and tariff pressures underscore the need for supply chain resilience and adaptive sourcing strategies. Segmentation across animal types, vaccine technologies, routes of administration, disease targets, and end-user contexts provides a pragmatic framework for prioritizing investments and customizing commercialization plans.

Executives who align R&D pipelines with operational agility, who invest in multi-regional regulatory competency, and who forge partnerships that combine scientific differentiation with manufacturing scale will be best positioned to capture long-term value. The pathways forward favor organizations that think systemically-integrating surveillance, vaccination programs, and post-market evidence generation-to deliver demonstrable outcomes for animal health, producer economics, and public health objectives. With disciplined execution and strategic foresight, stakeholders can convert current disruptions into durable competitive advantages.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of mRNA vaccine platforms for rapid response to emerging animal diseases
  • 5.2. Integration of digital tracking technologies for real-time monitoring of vaccine cold chain integrity in livestock
  • 5.3. Development of combined multivalent vaccines targeting multiple zoonotic pathogens in a single dose
  • 5.4. Growing adoption of nanoparticle adjuvant systems to enhance immunogenicity in veterinary vaccines
  • 5.5. Investment surge in autogenous vaccine production facilities for region-specific pathogen control in poultry
  • 5.6. Regulatory harmonization efforts to streamline vaccine approval across different global veterinary authorities
  • 5.7. Advances in recombinant viral vector platforms for improved safety and efficacy in companion animal vaccines
  • 5.8. Increased focus on plant-based vaccine expression systems for cost reduction and scalable animal immunization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary/Animal Vaccines Market, by Animal Type

  • 8.1. Aquaculture
  • 8.2. Cattle
  • 8.3. Companion Animals
    • 8.3.1. Cats
    • 8.3.2. Dogs
  • 8.4. Equine
  • 8.5. Poultry
  • 8.6. Swine

9. Veterinary/Animal Vaccines Market, by Vaccine Technology

  • 9.1. Conjugate
  • 9.2. Killed/Inactivated
  • 9.3. Live Attenuated
  • 9.4. Recombinant
  • 9.5. Subunit
  • 9.6. Toxoid

10. Veterinary/Animal Vaccines Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Nasal
  • 10.3. Oral

11. Veterinary/Animal Vaccines Market, by Disease Type

  • 11.1. Bacterial
  • 11.2. Parasitic
  • 11.3. Viral

12. Veterinary/Animal Vaccines Market, by End User

  • 12.1. Clinics
  • 12.2. Farms
    • 12.2.1. Aquaculture Farms
    • 12.2.2. Cattle Farms
    • 12.2.3. Equine Facilities
    • 12.2.4. Poultry Farms
    • 12.2.5. Swine Farms
  • 12.3. Veterinary Hospitals

13. Veterinary/Animal Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary/Animal Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary/Animal Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Boehringer Ingelheim GmbH
    • 16.3.2. Merck Animal Health
    • 16.3.3. Zoetis Inc.
    • 16.3.4. Hester Biosciences Limited
    • 16.3.5. Indian Immunologicals Ltd.
    • 16.3.6. Elanco Animal Health Incorporated
    • 16.3.7. Ceva Sante Animale
    • 16.3.8. Phibro Animal Health Corporation
    • 16.3.9. Huvepharma
    • 16.3.10. Arko Laboratories
    • 16.3.11. Anicon Labor GmbH
    • 16.3.12. Kemin Industries
    • 16.3.13. Hipra
    • 16.3.14. Vaxxinova
    • 16.3.15. Pfizer, Inc.
    • 16.3.16. Dechra Pharmaceuticals Limited
    • 16.3.17. Bimeda Biologicals Inc
    • 16.3.18. Neogen Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. VETERINARY/ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. VETERINARY/ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY/ANIMAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRAT